CG Oncology Inc. Common s... (CGON)
22.28
0.76 (3.53%)
At close: Apr 25, 2025, 3:59 PM
24.04
7.90%
After-hours: Apr 25, 2025, 05:56 PM EDT
3.53% (1D)
| Bid | 23.89 |
| Market Cap | 1.7B |
| Revenue (ttm) | 1.14M |
| Net Income (ttm) | -88.04M |
| EPS (ttm) | -1.41 |
| PE Ratio (ttm) | -15.8 |
| Forward PE | -13.29 |
| Analyst | Buy |
| Ask | 25.57 |
| Volume | 1,234,503 |
| Avg. Volume (20D) | 865,474 |
| Open | 21.10 |
| Previous Close | 21.52 |
| Day's Range | 21.01 - 22.28 |
| 52-Week Range | 14.80 - 46.99 |
| Beta | 1.61 |
About CGON
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 113
Stock Exchange NASDAQ
Ticker Symbol CGON
Analyst Forecast
According to 9 analyst ratings, the average rating for CGON stock is "Buy." The 12-month stock price forecast is $65, which is an increase of 191.74% from the latest price.
Stock ForecastsNext Earnings Release
CG Oncology Inc. Common stock is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+4.34%
CG Oncology shares are trading higher after TD Cow...
Unlock content with
Pro Subscription
4 months ago
-6.54%
CG Oncology shares are trading lower. The company announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer unresponsive to Bacillus Calmette Guerin.
